Industry News

Radius Health, Inc., a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research 2016 Annual Meeting, September 16-19, 2016, at the Georgia World Congress Center..."/>
Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016
Innoviva, Inc. announced today that it will report financial results for the second quarter ended June 30, 2016 after market close on Thursday July 28, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update. To participate in the live call dial 837-3908 from the U.S., or 890-8166 for international callers and enter Conference ID: 49092758."/>
Innoviva to Report Second Quarter 2016 Financial Results on July 28 at 5:00 p.m. EDT
Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Parminder“ Bobby” Singh, Ph.D., Corium’ s Chief Technology Officer and Vice President, Research and Development, will present clinical data from a Phase 1 pharmacokinetic study of Corium’ s once-weekly Corplex Donepezil product candidate at the..."/>
Corium to Present Clinical Data from a Phase 1 Pharmacokinetic Study of Once-Weekly Corplex™ Donepezil Transdermal System
Teva Pharmaceutical Industries Ltd. announced today that it successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands II B.V., consisting of the following tranches:. €1.75 billion of 0.375% fixed rate senior notes maturing in 2020; €1.50 billion of 1.125% fixed rate senior notes maturing in 2024; and €0.75 billion of 1.625% fixed rate senior notes maturing in 2028.. The notes will be sold at a price..."/>
Teva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that it intends to withdraw lomitapide from the European Union and certain other global markets. In addition, the Company is reducing approximately 13 percent of its global workforce. This represents a reduction from year-end 2015 of..."/>
Aegerion Pharmaceuticals Announces Cost Reduction Plans
HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing based HTG EdgeSeq system. There are approximately 79,000 non-Hodgkin lymphomas per year in the European Union, and as many as 40% of those are diagnosed as diffuse large B-cell lymphoma. The 2016 updates to the..."/>
HTG Molecular Diagnostics Obtains CE IVD Mark for Its HTG EdgeSeq DLBCL Cell of Origin Assay and HTG EdgeSeq System
Hill-Rom Holdings, Inc. announced today that its Board of Directors declared a fiscal year 2016 fourth quarter dividend of $0.17 per share. This quarterly dividend represents a 6 percent increase over the amount paid a year ago. The dividend is payable on September 30, 2016, to shareholders of record as of the close of business on September 16, 2016.."/>
Hill-Rom Declares Fourth Quarter 2016 Dividend
Abbott Laboratories' CEO remained guarded in his comments Wednesday about the company's proposed $5.8 billion acquisition of Alere, a health care diagnostics company, doing little to clear the uncertainty over whether the deal would be completed. "I have no particular predictions to make," said Miles White during a conference call about Abbott's second-quarter earnings. Abbott tried to terminate the merger agreement, announced in February, after Alere disclosed a U.S...."/>
Abbott CEO remains noncommittal on Alere deal [Chicago Tribune]
Teladoc, Inc., the first and largest telehealth platform in the United States, will release its second quarter 2016 operating results on Wednesday, August 3, 2016 after market close, with a conference call to follow at 5 p.m. Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 877-201-0168 or 647-788-4901 for international callers, and referencing participant code 46193070 approximately 15 minutes..."/>
Teladoc to Announce Second Quarter 2016 Operating Results and Host Conference Call on Wednesday, August 3, 2016
Span-America Medical Systems, Inc. announced that it plans to release its fiscal 2016 third quarter results on Thursday, August 4, after the close of regular trading. The company will conduct a conference call at 10:00 a.m. ET on Friday, August 5, to review the company's financial and operating results for the third quarter ended July 2, 2016. A live broadcast of the conference call will be available online at under..."/>
Span-America Medical Systems To Release Third Quarter Fiscal 2016 Results On August 4, 2016
Teva Pharmaceutical Industries Ltd. and its subsidiaries, including the Long-Term Issuer Default Rating, to' BBB' from' BBB+' and removed them from Rating Watch Negative. The Rating Outlook is Stable. Fitch has also assigned' BBB' ratings to the $15 billion bond issuance by Teva subsidiaries, the proceeds of which are expected to fund the pending acquisition of the generic pharmaceuticals business of Allergan plc."/>
Fitch Downgrades Teva Pharmaceuticals; Rates New Bonds 'BBB'
Cipher Pharmaceuticals Inc. today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016.. WHEN: Wednesday, August 10, 2016 at 8:30AM ET. CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through or"/>
Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call
Cipher Pharmaceuticals Inc. today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016.. WHEN: Wednesday, August 10, 2016 at 8:30AM ET. CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through or"/>
Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call
Insmed Incorporated. Investors who purchased or otherwise acquired shares between March 18, 2013 and June 8, 2016 inclusive, are encouraged to contact the Firm prior to the September 13, 2016 lead plaintiff motion deadline.. If you purchased shares of Insmed during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by..."/>
INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Insmed Incorporated and Reminds Investors with Losses to Contact the Firm
Medical Facilities Corporation announced today that a cash dividend payment of Cdn $0.09375 per common share will be payable on August 15, 2016 to holders of record of common shares at the close of business on July 29, 2016. This will be the Company's 148 th consecutive dividend payment since inception. The ex-dividend date for this distribution will be..."/>
Medical Facilities Corporation Announces July Dividend
Mylan Launches Generic Crestor® Tablets
Inovalon Holdings, Inc. securities pursuant and/or traceable to the Registration and Prospectus issued in connection with Inovalon’ s February 12, 2015 initial public offering. Investors suffering losses on their Inovalon investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at..."/>
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Inovalon Holdings, Inc. Investors and Encourages Investors to Contact the Firm
CytRx Corporation concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors. CytRx is a biopharmaceutical research and development company that specializes in oncology."/>
Glancy Prongay & Murray Commences Investigation on Behalf of CytRx Corporation Investors

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology664 Articles
Financials633 Articles
Consumer Discretionary562 Articles
Industrials401 Articles
Health Care386 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at